» Articles » PMID: 28747497

Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates After and Passage

Overview
Journal J Virol
Date 2017 Jul 28
PMID 28747497
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Human respiratory syncytial virus (RSV) is the leading etiologic agent of lower respiratory tract infections in children, but no licensed vaccine exists. Previously, we developed two parainfluenza virus 5 (PIV5)-based RSV vaccine candidates that protect mice against RSV challenge. PIV5 was engineered to express either the RSV fusion protein (F) or the RSV major attachment glycoprotein (G) between the hemagglutinin-neuraminidase (HN) and RNA-dependent RNA polymerase (L) genes of the PIV5 genome [PIV5-RSV-F (HN-L) and PIV5-RSV-G (HN-L), respectively]. To investigate the stability of the vaccine candidates , they were passaged in Vero cells at high and low multiplicities of infection (MOIs) for 11 generations and the genome sequences, growth kinetics, and protein expression of the resulting viruses were compared with those of the parent viruses. Sporadic mutations were detected in the consensus sequences of the viruses after high-MOI passages, and mutation rates increased under low-MOI-passage conditions. None of the mutations abolished antigen expression. Increased numbers of mutations correlated with increased growth rates , indicating that the viruses evolved through the course of serial passages. We also examined the stability of the vaccine candidates after a single passage in African green monkeys. No mutations were detected in the consensus sequences of viruses collected from the bronchoalveolar lavage (BAL) fluid of the animals. , mutations in RSV G and PIV5 L were found in individual isolates of PIV5-RSV-G (HN-L), but plaque isolates of PIV5-RSV-F (HN-L) had no mutations. To improve upon the PIV5-RSV-F (HN-L) candidate, additional vaccine candidates were generated in which the gene for RSV F was inserted into earlier positions in the PIV5 genome. These insertions did not negatively impact the sequence stability of the vaccine candidates. The results suggest that the RSV F and G gene insertions are stable in the PIV5 genome. However, the function of the foreign gene insertion may need to be considered when designing PIV5-based vaccines. The genetic stability of live viral vaccines is important for safety and efficacy. PIV5 is a promising live viral vector and has been used to develop vaccines. In this work, we examined the genetic stability of a PIV5-based RSV vaccine and We found that insertions of foreign genes, such as the RSV F and G genes, were stably maintained in the PIV5 genome and there was no mutation that abolished the expression of RSV F or G. Interestingly, the function of the inserted gene may have an impact on PIV5 genome stability.

Citing Articles

Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year.

Gingerich M, Nair N, Azevedo J, Samanta K, Kundu S, He B NPJ Vaccines. 2024; 9(1):33.

PMID: 38360853 PMC: 10869809. DOI: 10.1038/s41541-023-00802-y.


Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.

Li H, Sun H, Tao M, Han Q, Yu H, Li J J Virol. 2024; 98(3):e0112923.

PMID: 38305155 PMC: 10949453. DOI: 10.1128/jvi.01129-23.


Transplacental Antibody Transfer of Respiratory Syncytial Virus Specific IgG in Non-Human Primate Mother-Infant Pairs.

Citron M, McAnulty J, Callahan C, Knapp W, Fontenot J, Morales P Pathogens. 2021; 10(11).

PMID: 34832599 PMC: 8624788. DOI: 10.3390/pathogens10111441.


Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates.

Xiao P, Dienger-Stambaugh K, Chen X, Wei H, Phan S, Beavis A Front Immunol. 2021; 12:623996.

PMID: 33717130 PMC: 7946978. DOI: 10.3389/fimmu.2021.623996.


Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.

Li K, Li Z, Wohlford-Lenane C, Meyerholz D, Channappanavar R, An D mBio. 2020; 11(2).

PMID: 32265331 PMC: 7157776. DOI: 10.1128/mBio.00554-20.


References
1.
Phan S, Zengel J, Wei H, Li Z, Wang D, He B . Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge. J Virol. 2017; 91(19). PMC: 5599740. DOI: 10.1128/JVI.00560-17. View

2.
Karron R, Wright P, Belshe R, Thumar B, Casey R, Newman F . Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005; 191(7):1093-104. DOI: 10.1086/427813. View

3.
Tompkins S, Lin Y, Leser G, Kramer K, Haas D, Howerth E . Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology. 2007; 362(1):139-50. PMC: 1995462. DOI: 10.1016/j.virol.2006.12.005. View

4.
Li Z, Gabbard J, Mooney A, Chen Z, Tompkins S, He B . Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice. J Virol. 2013; 87(17):9604-9. PMC: 3754099. DOI: 10.1128/JVI.01289-13. View

5.
Anderson L, Dormitzer P, Nokes D, Rappuoli R, Roca A, Graham B . Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013; 31 Suppl 2:B209-15. PMC: 3919153. DOI: 10.1016/j.vaccine.2012.11.106. View